This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

Re-treatment Redux

Raymond S. Koff, MD

JAMA. 2001;285:212-214.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In the past decade, chronic hepatitis due to hepatitis C virus (HCV) infection has emerged as the predominant liver disease in the United States. While progression of chronic hepatitis C to cirrhosis may be slow, end-stage liver disease due to HCV-associated cirrhosis is now the single most common indication for liver transplantation, and HCV-associated cirrhosis is responsible for the increasing incidence of hepatocellular carcinoma in this country.¹ Direct costs of care for patients with progressive disease are high, treatment is expensive, and the national economic burden of hepatitis C has been projected to increase dramatically in the future.² Fortunately, progress in antiviral treatment has been steady and impressive.

Permanent serum HCV RNA clearance is the principal goal of antiviral treatment and now can be achieved in about 40% of patients treated with the current regimen of interferon alfa and ribavirin (combination therapy).³ A sustained virological response . . . [Full Text of this Article]

Author Affiliation: Department of Medicine, Division of Digestive Disease and Nutrition, University of Massachusetts, Memorial Health Care, Worcester.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Interferon and Ribavirin vs Interferon Alone in the Re-treatment of Chronic Hepatitis C Previously Nonresponsive to Interferon: A Meta-analysis of Randomized Trials
Kristin J. Cummings, Shing M. Lee, Emily S. West, Javier Cid-Ruzafa, Steven G. Fein, Yutaka Aoki, Mark S. Sulkowski, and Steven N. Goodman
JAMA. 2001;285(2):193-199.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data
Camma et al.
Gut 2002;51:864-869.
ABSTRACT | FULL TEXT